Oak Hill Bio and Chiesi Group Initiate Clinical Study
In a groundbreaking step for neonatal care, Oak Hill Bio and Chiesi Group recently announced the enrollment of the first patient in a significant clinical study. This Phase 2b study aims to evaluate OHB-607, a promising investigational drug candidate designed to prevent bronchopulmonary dysplasia (BPD), a serious condition affecting infants born extremely prematurely.
The Importance of Addressing BPD
Bronchopulmonary dysplasia remains the most common complication among preterm infants, impacting a significant proportion of those born at less than 28 weeks' gestation. With no approved therapies available to address this critical issue, the launch of this clinical study represents a beacon of hope. The significance lies not only in the potential medical breakthroughs but also in improving the quality of life for vulnerable infants.
“As a neonatologist, I’m thrilled to see this clinical trial resume,” shared Victoria Niklas, Chief Medical Officer at Oak Hill Bio. “The research we are conducting holds the promise of better outcomes for infants facing the challenges of extreme prematurity.” Oak Hill Bio is dedicated to advancing the field and enhancing care in neonatology.
A Collaborative Effort for Progress
Oak Hill Bio and Chiesi Group have joined forces, demonstrating a shared commitment to advancing healthcare solutions for extremely premature infants. Diego Ardigò, Executive Vice President of Global Research & Development at Chiesi, emphasized the moral responsibility in addressing the medical needs of these infants. This collaboration will not only further scientific exploration, but also contribute positively toward enhancing patient outcomes.
About the Phase 2b Study
The Phase 2b study is meticulously designed as a multicenter, randomized, open-label, two-arm study. It assesses the efficacy and safety of OHB-607 compared to standard neonatal care. Targeting infants born between 23 and 28 weeks of gestation, the study is expanding its reach from the United States to several European countries, including Finland, Germany, and the UK, among others.
In total, the study aims to enroll at least 105 infants throughout Europe. This initiative not only significantly broadens the scope of the earlier trials, but also brings insights from diverse populations to understand the treatment's effects comprehensively.
Study Administration and Goals
OHB-607 will be administered through continuous intravenous infusion starting 24 hours after birth and continuing until the infants reach 30 weeks postmenstrual age. The overarching goal of the study is to evaluate whether the treatment can reduce the incidence of severe BPD or death by the age of 36 weeks when compared to standard neonatal care alone.
The Potential of OHB-607
OHB-607 is designed to restore crucial levels of insulin-like growth factor-1 (IGF-1) in preterm infants. Low levels of IGF-1 after preterm birth have been associated with increased risks of BPD and other complications impacting long-term health, including neurodevelopmental deficits.
This investigative drug is under consideration for its capability to improve lung development, thereby potentially lessening the need for respiratory support. The safety and effectiveness of OHB-607 could represent a pivotal advancement in pediatric medicine, particularly as it addresses concerns that have historically lacked satisfactory treatment options.
Understanding BPD's Broader Impact
Bronchopulmonary dysplasia extends beyond complications in lung function. It can result in increased mortality, prolonged hospitalization, and higher parental health costs. It can also lead to disabilities affecting both respiratory and neurological health.
The multifactorial nature of BPD highlights gestational age as a key predictor, with other contributing factors like birth weight and overall care practices playing a role. This underscores the critical need for effective treatments like OHB-607, which aims to mitigate severity and influence long-term health positively.
About Oak Hill Bio
Oak Hill Bio Ltd is at the forefront of innovation in neonatology and therapeutics for rare diseases. The company is committed to developing life-saving medications that cater to the unique needs of extremely preterm infants. With operations across the United States and the UK, Oak Hill Bio is advancing a promising pipeline of clinical-stage therapies, working towards groundbreaking results for newborns in need.
About Chiesi Group
Chiesi Group is a distinguished biopharmaceutical company focusing on innovative treatments in respiratory health and rare diseases. Their mission encompasses not only improving health outcomes but also fostering environmental and community well-being. Through initiatives like achieving Net-Zero greenhouse gases by 2035, Chiesi Group is committed to sustainable practices that enhance overall quality of life.
Frequently Asked Questions
What is the aim of the Phase 2b clinical study?
The study aims to evaluate the efficacy and safety of OHB-607 for the prevention of bronchopulmonary dysplasia in extremely premature infants.
How will OHB-607 be administered to infants?
OHB-607 will be administered through continuous intravenous infusion starting 24 hours after birth and lasting until 30 weeks postmenstrual age.
What is bronchopulmonary dysplasia (BPD)?
BPD is a serious lung condition that affects premature infants, commonly occurring in those born at under 28 weeks of gestation.
Why is IGF-1 important in the treatment?
IGF-1 supports the growth and development of crucial organs, and its administration may improve outcomes for preterm infants.
What long-term outcomes could the study evaluate?
The study will assess long-term respiratory outcomes, neurodevelopment, and the incidence of other complications of prematurity.
